Pfizer (NYSE:PFE) Receives Hold (C-) Rating from Weiss Ratings

Key Points

• Pfizer's stock rating has been reiterated as "hold (C-)" by Weiss Ratings, amidst a mix of ratings from other brokerages, including "neutral" from UBS Group with a target price of $28.00.
• The company's latest quarterly earnings report showed an EPS of $0.78, exceeding expectations, with revenue of $14.65 billion, marking a year-over-year increase of 10.3%.
• Pfizer's stock currently has a market capitalization of $140.92 billion, with a consensus "Hold" rating and an average target price of $28.13 based on analyst evaluations.

Pfizer (NYSE:PFE - Get Free Report)'s stock had its "hold (c-)" rating reiterated by analysts at Weiss Ratings in a note issued to investors on Saturday,Weiss Ratings reports.

Several other brokerages also recently weighed in on PFE. UBS Group reaffirmed a "neutral" rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Morgan Stanley cut their target price on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a research note on Friday, October 10th. Wall Street Zen downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. Bank of America upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research note on Friday, October 3rd. Finally, Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $28.13.

Pfizer Trading Up 0.5%

Shares of PFE stock traded up $0.12 during trading hours on Friday, hitting $24.79. The company had a trading volume of 27,403,893 shares, compared to its average volume of 58,973,096. The company's fifty day moving average is $24.87 and its 200 day moving average is $24.18. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer has a fifty-two week low of $20.92 and a fifty-two week high of $29.17. The stock has a market capitalization of $140.92 billion, a PE ratio of 13.18, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the business posted $0.60 EPS. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts expect that Pfizer will post 2.95 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PFE. GKV Capital Management Co. Inc. purchased a new position in shares of Pfizer in the 1st quarter valued at $27,000. Curio Wealth LLC boosted its stake in Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 1,098 shares during the period. North Capital Inc. acquired a new stake in Pfizer during the 1st quarter worth $28,000. Bayforest Capital Ltd acquired a new stake in Pfizer during the 1st quarter worth $28,000. Finally, Harbor Asset Planning Inc. acquired a new stake in Pfizer during the 2nd quarter worth $29,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.